Glibenclamide has been shown to prevent and alleviate DM atrial structural remodeling by activating the NLRP3-inflammasome/caspase-1/Gal-3 signaling pathway, thereby decreasing NLRP3 and Gal-3 expression that is induced by DM [105]. This evidence concerns the gene NLRP3 and diabetes mellitus.